Stay updated with the latest dermatology news, research highlights, FDA approvals, and industry developments.
The FDA has granted approval for a new IL-13 inhibitor biologic for pediatric patients aged 6-11 with moderate-to-severe atopic dermatitis.
Researchers have found a significant correlation between gut microbiome composition and the severity of psoriatic disease in a large-scale clinical study.
A new artificial intelligence system for melanoma detection has demonstrated diagnostic accuracy matching that of experienced dermatologists in a multi-center validation study.
The American Academy of Dermatology has released updated evidence-based guidelines for the management of acne vulgaris in adult patients.
A novel oral JAK inhibitor has shown remarkable repigmentation results in Phase 3 vitiligo trials, potentially transforming treatment for this challenging condition.
New data shows teledermatology visits now account for 25% of all dermatology consultations, with growing acceptance among both patients and providers.
A new topical JAK inhibitor formulation for alopecia areata has entered Phase 3 clinical trials after promising Phase 2 results showing significant hair regrowth.
The FDA has finalized updated testing standards for sunscreen products, including new requirements for UVA protection claims and water resistance testing.
Preliminary research suggests that GLP-1 receptor agonists may have beneficial effects on inflammatory skin conditions including psoriasis and hidradenitis suppurativa.
A new workforce analysis projects a shortage of over 4,000 dermatologists in the US by 2030, with rural areas facing the greatest access challenges.
A novel triple-combination topical therapy for melasma has demonstrated superior efficacy compared to standard hydroquinone monotherapy in a randomized controlled trial.
Researchers have demonstrated successful in-situ 3D bioprinting of skin grafts directly onto burn wounds, achieving faster healing times in preclinical studies.